Mr. Shafin Tejani reports

VICTORY SQUARE TECHNOLOGIES REPORTS 2024 ACHIEVEMENTS AND OUTLINES 2025 STRATEGIC VISION

Victory Square Technologies Inc. has provided its latest corporate update. The report highlights significant milestones achieved in 2024 and strategic priorities aimed at driving innovation and shareholder value in 2025.

• Significant net income growth: Victory Square achieved $10.7-million in Q3 net income.
• Unaudited net asset value (NAV): Estimated at $127,524,464 as of Jan. 28, 2025.
• Digital health expansion: The VSDHOne platform powers health care brands across all 50 U.S. states, offering telehealth, compliance solutions and direct-to-consumer scalability.
• Hydreight Technologies' milestones: Hydreight ranked No. 56 on the 2024 Deloitte Technology Fast 500, achieved profitability in 2024, and launched a $10-million health accelerator to foster the next generation of digital health entrepreneurs.
• Diabetes care advancements: Insu Therapeutics is developing oral delivery technology for insulin and peptide-based drugs, targeting the $118-billion global diabetes market.
• Sustainability in action: Stardust Solar expands into Houston, partners with Tesla and raises $1.2-million to support renewable energy initiatives.
• Frontier Technologies: EdgeTI advances quantum computing applications, while XR Immersive integrates continuous glucose monitoring (CGM) technology for enhanced diabetes management.
• 2025 vision: Strategic focus on scaling digital health solutions, accelerating portfolio growth and enhancing shareholder value.

To our valued shareholders,

As we enter 2025, Victory Square Technologies remains focused on advancing digital health and driving meaningful innovation. The health care sector is undergoing significant transformation, influenced by rising costs, an aging population and rapid technological advancements.

Digital health presents a major opportunity to enhance accessibility, efficiency and patient outcomes. As Marc Andreessen noted, "Health care is undergoing a software revolution." Victory Square is committed to leveraging this shift to develop scalable, patient-centric solutions that create long-term value for both the health care industry and our shareholders.

Hydreight Technologies: scaling direct-to-consumer health care

Hydreight Technologies (TSX-V: NURS) (OTCQB: HYDTF) (FSE: SO6) continues to demonstrate strong growth and industry impact:

• Deloitte Technology Fast 500 recognition: Ranked No. 56, with a three-year revenue compound annual growth rate (CAGR) of 54 per cent (source: Deloitte Fast 500 Report).
• Expanding provider network: Over 2,500 nurses, 100 doctors and a 503B pharmacy network covering all 50 U.S. states.
• Achieved profitability in 2024: A milestone reflecting operational efficiency, market leadership and a scalable business model (source: company press release).
• $10-million health accelerator program: In partnership with Victory Square, Hydreight is investing in early stage digital health companies using the VSDHOne platform to enable scalable growth (source: company press release).
• Expanded telehealth offerings: New services include GLP-1 medications, genetic testing and hormone replacement therapy, addressing a broad range of patient needs.
• Launch of VSDHOne: Strengthening digital health infrastructure and supporting business growth across multiple health care sectors.

Strategic partnership: Hydreight and The DRIPBaR

Hydreight Technologies has partnered with The DRIPBaR to launch DRIPBaR Direct, a nationwide direct-to-consumer health care initiative powered by the VSDHOne platform. This collaboration enables The DRIPBaR to offer seamless telehealth consultations and physician-prescribed wellness treatments across the country, leveraging a compliant infrastructure and competitive pricing models comparable to established brands like HIMS (source: company press release).

Portfolio expansion beyond digital health

Insu Therapeutics:

• University of British Columbia (UBC) spinoff developing oral drug delivery technologies for diabetes care.
• Targeting the $118-billion global diabetes drug market, addressing a growing patient population of over 783 million individuals.
• Advancing regulatory approvals with FDA (Food and Drug Administration) and EMA (European Medicines Agency) for innovative peptide-based treatments.

Stardust Solar (TSX-V: SUN):

• Expanded U.S. operations with a Houston franchise launch (source: company announcement).
• Partnered with Tesla to accelerate renewable energy adoption (source: Tesla collaboration agreement).
• Raised $1.2-million in an oversubscribed private placement (source: company press release).

Edge Total Intelligence (TSX-V: CTRL):

• Developing quantum computing applications and digital twin technology (source: company update).
• Secured $5-million in private placement financing for product development (source: financial press release).

XR Immersive Technologies (CSE: VRAI):

• Acquired InsulinQ's CGM technology to enhance diabetes management solutions (source: acquisition announcement).

Financial strength and growth outlook:

• Q3 2024 financial results: Net income of $10,661,274 and earnings per share of 11 cents, demonstrating strong execution and growth.
• Unaudited net asset value (NAV): Estimated at $127,524,464 as of Jan. 28, 2025.

"At Victory Square, we measure success through key performance indicators that reflect our growth: cash invested, net asset value (NAV), return on invested cash, share price/market cap versus index benchmark and operating costs as a per cent of NAV. Since 2017, we have evaluated over 1,000 companies, selecting 25 for investment. To date, we have invested $13-million, and the value of our portfolio has grown from $4-million in 2017 to approximately $127-million today. Our goal remains clear: to continue scaling NAV and driving long-term shareholder value," said Shafin Diamond Tejani, chief executive officer, Victory Square Technologies

Strategic focus: digital health and expansion

Victory Square's continued emphasis on digital health is aligned with market demand for scalable, patient-centric health care solutions. Through Hydreight and VSDHOne, Victory Square is:

• Enabling businesses to scale: Providing a compliant telehealth infrastructure for nationwide expansion.
• Diversifying health care offerings: Supporting businesses in offering GLP-1 medications, lab testing, ED treatments, hair loss solutions, NAD therapy, genetic testing and hormone replacement therapy.
• Accelerating portfolio growth: Strengthening partnerships and acquisitions to enhance revenue and market reach.

Looking ahead: 2025 growth strategy

In 2025, Victory Square is focused on:

• Expanding digital health infrastructure: Strengthening VSDHOne as a leading telehealth platform.
• Fueling portfolio growth: Supporting companies with capital and resources to scale efficiently.
• Enhancing shareholder value: Driving NAV growth and generating sustainable long-term returns.

"Victory Square is committed to advancing technology and healthcare solutions that improve accessibility and patient outcomes. Our 2024 results demonstrate our strategic execution, and we are focused on continuing this momentum into 2025 and beyond," said Mr. Tejani, chairman and CEO, Victory Square Technologies.

Join the company in 2025

Victory Square invites investors partners, and stakeholders to be part of its journey in shaping the future of digital health and technology-driven innovation.

About Victory Square Technologies Inc.

Victory Square Technologies builds, acquires and invests in promising start-ups across various industries, including artificial intelligence, gaming, blockchain, clean technology and digital health. Through its dynamic ecosystem, Victory Square nurtures and scales innovative companies, creating long-term value for shareholders.

We seek Safe Harbor.